Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

ale patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen.

Contraindications

PEGINTRON is contraindicated in patients with known hypersensitivity reactions such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens Johnson syndrome and toxic epidermal necrolysis to interferon alpha or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic CHC patients before or during treatment. PEGINTRON/REBETOL combination therapy is additionally contraindicated in women who are pregnant or may become pregnant (see Boxed Warning and Pregnancy section), men whose female partners are pregnant, patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia), and patients with creatinine clearance less than 50 mL per min.

Pregnancy

REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during therapy and 6 months post-treatment. Patients should use at least two effective forms of contraception and have monthly pregnancy tests during therapy and for 6 months after completion of therapy. If this drug is used during pregnancy or if a patient becomes pregnant, the patient should be apprised of the potential hazard to a fetus. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/pjbxjd/us_aco_it ) ... IT Spending Outlook 2018" report to their offering. ... covered by ACO would grow at a CAGR of ... IT spending has been studied on three main grounds ... on services. Our research provides current market estimation and ...
(Date:5/1/2015)... PRINCETON, N.J. , May 1, 2015 ... it has expanded its current therapeutic focus ... and other serious psychiatric disorders. Braeburn has ... atypical (or second-generation) antipsychotic risperidone for treatment ... risperidone acquisition Braeburn acquires global rights to ...
(Date:5/1/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), an ... markets products that assist healthcare providers in monitoring patients ... the first quarter ended March 31, 2015. ... continued progress with year over year growth of 44% ... said Doug Murphy-Chutorian , M.D., chief executive officer ...
Breaking Medicine Technology:United States ACO IT Spending Outlook 2014-2018 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5
... Life Spine, a medical device company that designs, develops, ... spinal disorders, announced today amidst consolidations in the industry ... its history. As a full line spine company Life ... sacrum. Aileron™, a minimally invasive adjustable InterSpinous ...
... China, Nov. 4, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited ... marketer of medical devices worldwide, today announced that it will ... fair to be held between November 16 and 19 in ... H2 C07 at the 43rd World Forum of Medicine - ...
Cached Medicine Technology:Mindray Medical to Exhibit at MEDICA 2011 in Dusseldorf, Germany from November 16-19, 2011 2Mindray Medical to Exhibit at MEDICA 2011 in Dusseldorf, Germany from November 16-19, 2011 3
(Date:5/2/2015)... “ ActOn ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... a difference. , In this material world, almost everything is ... money, which is why those things should be prioritized above ...
(Date:5/2/2015)... May 02, 2015 We are pleased ... Delray Recovery Center as one of the Top Workplaces ... in the addiction treatment field for their ethics and ... innovate and to continue their educational efforts. The Delray ... environment, never forgetting their purpose – to help individuals ...
(Date:5/2/2015)... 02, 2015 Kare Visits LLC. launched in ... busy caregivers. Kare Visits offers relief for caregivers by ... facilities. According to the Caregiver Action Network, eight ... of 20 hours a week caring for an elderly or ... to hire a nurse, a caregiver is now empowered to ...
(Date:5/2/2015)... 02, 2015 With the success that Veatch ... proud to welcome Neida Miranda and Alex Shields to the ... has over 41 years of combined experience working with dentists ... the dental field for 8 years. She was certified ... Texas. Customer service, positive attitude and showing the importance of ...
(Date:5/1/2015)... 01, 2015 Pioneer Millworks, the largest ... latest in their reclaimed wood products at the 27th ... Javits Center in NYC this May. Their newest offerings, ... much anticipated texture and color to North America's platform ... of texture and color in the design world and ...
Breaking Medicine News(10 mins):Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3
... AstraZeneca (NYSE: AZN ) is aware ... (FDA) posted to its web site -- and subsequently ... Psychopharmacologic Drugs Advisory Committee (PDAC) meeting. The PDAC meeting ... provided in supplemental new drug applications (sNDA) for SEROQUEL ...
... to help men and women from the United Kingdom (UK) and Europe who ... has opened its London center. , ... (PRWEB) April 3, 2009 -- In its continued ... who are thinning and balding, Nu/Hart Hair Clinics , a world leader ...
... April 3 Recently, researchers at the University ... conducted a study of U.S. hospitals and discovered that ... year. The study recommended solutions, including location-based technology, to ... of this study come at a time when Versus ...
... WARSAW, Ind., April 3 Zimmer Holdings, Inc. (NYSE: ... 2009 sales and earnings conference call will be broadcast live ... a.m. Eastern Time. A news release detailing the quarterly ... of the conference call.The live audio webcast can be accessed ...
... radiation dose delivered to patients undergoing coronary CT ... using tube current modulation, according to a study ... PA. , The study included 172 patients ... tube current modulation and 95 patients who were ...
... Researchers from Boston University School of Medicine,s (BUSM) ... traits associated with healthy aging and longevity amongst ... in collaboration with scientists from the National Institute ... the Journal of the American Geriatrics Society ...
Cached Medicine News:Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 2Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 3Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 4Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 5Health News:Nu/Hart, World Leader in Hair Transplants, Opens London Centre 2Health News:Nu/Hart, World Leader in Hair Transplants, Opens London Centre 3Health News:Versus Technology to Showcase Leading Enterprise Patient and Clinical Workflow Solutions at HIMSS 2009 2Health News:Versus Technology to Showcase Leading Enterprise Patient and Clinical Workflow Solutions at HIMSS 2009 3Health News:Versus Technology to Showcase Leading Enterprise Patient and Clinical Workflow Solutions at HIMSS 2009 4Health News:Radiation dose can be reduced for 'triple rule-out' coronary CT angiography 2Health News:Researchers identify personality traits 2
... low profile implantable bipolar fixed screw-in ... either the atrium or the ventricle. ... a screwdriver shape stylet which is ... ring tip and fixation screw are ...
... are implantable bipolar extendable/retractable screw-in permanent ... the atrium or the ventricle. The ... extended or retracted by turning the ... an anti-chattering mechanism for steady pacing ...
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Used to occupy an empty hole which is not being used in an implantablepacemaker header....
Medicine Products: